Advanced Chemotherapy Technologies Achieves $5.5M Series A Financing: Company to Pursue First Clinical Trials of ACT-IOP-003 Targeting Advanced Pancreatic Cancer
The capital will be used to fund initial clinical development of the company’s ACT-IOP-003 local chemotherapy system for the treatment of locally advanced non-resectable and borderline resectable pancreatic cancer.